Squarepoint
PDSB icon

Squarepoint’s PDS Biotechnology PDSB Stock Holding History

Squarepoint’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,556
Closed -$148K – 4795
2025
Q4 		$148K Sell
192,556
-99,071
-34% -$89.4K ﹤0.01% 3949
2025
Q3 		$295K Buy
291,627
+193,862
+198% +$228K ﹤0.01% 3689
2025
Q2 		$130K Buy
+97,765
New +$133K ﹤0.01% 4098
2024
Q3 		– Sell
-40,979
Closed -$120K – 4551
2024
Q2 		$120K Buy
+40,979
New +$131K ﹤0.01% 3762
2024
Q1 		– Sell
-13,011
Closed -$64.7K – 4460
2023
Q4 		$64.7K Buy
13,011
+1,935
+17% +$9.62K ﹤0.01% 3823
2023
Q3 		$55.9K Sell
11,076
-27,441
-71% -$150K ﹤0.01% 3624
2023
Q2 		$194K Sell
38,517
-64,004
-62% -$419K ﹤0.01% 3234
2023
Q1 		$631K Buy
+102,521
New +$839K ﹤0.01% 2167

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Squarepoint's PDSB Position: Q1 2026 in Review

Squarepoint sold out of PDS Biotechnology (PDSB) in Q1 2026, closing a stake of 192,556 shares — an estimated $148K sold.

Squarepoint first reported a position in PDSB in Q1 2023 and held it in 8 quarters. The position peaked at $631K in Q1 2023. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Squarepoint reported no remaining PDS Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 192,556 PDS Biotechnology shares in Q1 2026, an estimated $148K.
  • Squarepoint first reported a position in PDS Biotechnology in Q1 2023 and held it in 8 quarters.
  • Squarepoint's PDS Biotechnology position peaked at $631K in Q1 2023.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.